{"filings":[{"id":1562121,"accession_number":"0001140361-26-028154","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2026-07-10T01:03:42+00:00","items":["7.01","9.01"],"status":"ready","headline":"Ionis reaffirms FY 2026 financial guidance unchanged from April 29 release","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reaffirmed FY 2026 financial guidance on July 9, 2026.","Guidance unchanged from that provided on April 29, 2026 in Q1 earnings release.","No specific financial figures disclosed in this filing; refer to prior release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1550476,"accession_number":"0001140361-26-028092","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2026-07-09T18:55:22+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Ionis eplontersen Phase 3 ATTR-CM trial misses primary endpoint; monotherapy subgroup shows nominal benefit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CARDIO-TTRansform trial did not meet primary composite endpoint of CV mortality and recurrent CV events vs placebo at Week 140.","In prespecified subgroup, eplontersen monotherapy showed nominally significant HR of 0.71 on the composite outcome.","57% of patients on stabilizer at baseline; no treatment effect observed in that subgroup.","Secondary, imaging, and biomarker analyses favored eplontersen; safety profile consistent with prior results.","Full results to be presented at ESC Congress in August 2026; Ionis and AstraZeneca continue analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-07-09","daily_digest_url":"/daily/2026-07-09","daily_digest_rank":10},{"id":1248636,"accession_number":"0001140361-26-026232","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2026-06-24T19:48:37+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA approves Ionis' TRYNGOLZA for severe hypertriglyceridemia, cuts pancreatitis risk 91%","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved TRYNGOLZA (olezarsen) as adjunct to diet to reduce triglycerides and risk of acute pancreatitis in adults with sHTG (TG ≥500 mg/dL).","Phase 3 CORE/CORE2: fasting TG lowered up to 72% vs placebo at 6 months; acute pancreatitis events reduced up to 91%.","86% of patients achieved TG <500 mg/dL at 12 months; NNT to prevent one acute pancreatitis: 20 overall, 4 in highest-risk subgroup.","Available in 50 mg or 80 mg dose, self-administered monthly via autoinjector; U.S. launch expected in July 2026.","This is Ionis' first independent commercial launch in a prevalent disease, marking a major milestone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-06-24","daily_digest_url":"/daily/2026-06-24","daily_digest_rank":4},{"id":1023036,"accession_number":"0001140361-26-025050","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2026-06-12T18:20:32+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ionis olezarsen OLE data: liver fat returns toward baseline after 24 months; 90%+ retention","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean hepatic fat fraction (HFF) levels returned toward baseline after 24 months of olezarsen 80 mg in CORE-OLE study of severe hypertriglyceridemia.","Patients transitioning from 50 mg to 80 mg showed less pronounced HFF changes; safety profile remained favorable with longer treatment.","Over 90% of eligible patients from CORE/CORE2 studies enrolled and remained in the open-label extension.","Data presented at National Lipid Association Scientific Sessions in Chicago on June 12, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":910276,"accession_number":"0001140361-26-024407","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2026-06-08T16:49:43+00:00","items":["5.02","7.01","5.07","9.01"],"status":"ready","headline":"Ionis appoints Ludwig Hantson to board; shareholders approve equity plan amendments","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ludwig Hantson, former Alexion CEO, appointed to board effective June 4, 2026.","Peter Reikes also appointed to board; directors Joseph Wender and Lynne Parshall retired.","Shareholders approved increase of 2011 equity plan by 9.5M shares to 52M total.","ESPP amended to add 750k shares and remove termination date; Ernst & Young ratified as auditor.","Advisory vote on executive compensation passed with ~135.5M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":713396,"accession_number":"0001140361-26-023093","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2026-05-28T16:41:22+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Bepirovirsen Phase 3 achieves 19% functional cure rate in chronic hepatitis B; Q3 2026 FDA decision expected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["19% functional cure rate (233/1,220) vs 0% placebo (p<0.001) in overall population (HBsAg ≤3000 IU/mL).","26% functional cure rate in patients with ≤1000 IU/mL HBsAg, representing ~45% of diagnosed CHB cases globally.","49% of bepirovirsen recipients achieved qHBsAg ≤100 IU/mL one year post-treatment in exploratory analysis.","Bepirovirsen under priority FDA review (Breakthrough/Fast Track); first regulatory decisions anticipated in Q3 2026.","Ionis eligible for tiered royalties of 10-12% on net sales plus milestones under 2019 GSK license."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99315,"accession_number":"0001140361-26-017637","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ionis Q1 revenue up 87% to $246M; raises 2026 guidance; olezarsen sHTG peak sales view >$3B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $246M (+87% YoY); GAAP operating loss $118M; non-GAAP loss $75M.","TRYNGOLZA net sales $27M; DAWNZERA $16M (+125% QoQ); royalties $58M, R&D revenue $138M incl. $95M milestones.","2026 guidance raised: total revenue $875-900M (from $800-825M); non-GAAP op. loss $425-475M (from $500-550M).","Olezarsen sHTG sNDA accepted for Priority Review (PDUFA June 30); peak net sales guidance raised to >$3B.","Zilganersen NDA for Alexander disease accepted Priority Review (PDUFA Sept 22); bepirovirsen NDA also accepted."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":246091000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99314,"accession_number":"0001140361-26-015801","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Ionis zilganersen meets primary endpoint in Alexander disease; PDUFA Sept 22, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: gait speed stabilized vs control at Week 61 (LS mean diff 33.3%, p=0.041) in patients ≥5 years.","GMFM-88 in children 2-4 years showed 22.9-point improvement vs control (nominal p=0.034).","Key secondary endpoints (MBS, PGIS, PGIC, CGIC) consistently favored zilganersen over control.","Serious TEAEs less frequent on zilganersen (37.5%) vs control (47.1%); most AEs mild/moderate.","FDA Priority Review with PDUFA action date set for September 22, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115245,"accession_number":"0001140361-26-008340","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Ionis announces retirement of two long-serving directors and appointment of Peter Reikes to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["B. Lynne Parshall and Joseph Wender retiring at end of term in June 2026 after 25+ years on the board.","Peter N. Reikes to rejoin board effective June 4, 2026; he previously served from 2018-2021.","Reikes most recently senior strategy advisor for ARPA-H and senior advisor to FDA.","Both departing directors received Ionis Career Achievement Award; company thanks them."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115244,"accession_number":"0001140361-26-006718","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ionis FY2025 total revenue $944M (+34% YoY); guides 2026 rev $800-825M, op loss $500-550M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 total revenue $944M (2024: $705M); Q4 revenue $203M.","TRYNGOLZA net sales $108M in first launch year; DAWNZERA $7M in first full quarter.","SPINRAZA royalties $212M, WAINUA royalties $49M; collaborative rev $508M incl $280M Ono upfront.","2026 guidance: revenue $800-825M, non-GAAP op loss $500-550M, cash ~$1.6B.","Olezarsen sNDA for sHTG submitted; zilganersen NDA for Alexander disease decision H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":203330000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115243,"accession_number":"0001140361-26-000893","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ionis reports TRYNGOLZA 2025 preliminary U.S. net sales of $105M, ups peak olezarsen guidance to >$2B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["TRYNGOLZA generated $105M in preliminary 2025 U.S. net product sales, outperforming expectations as first FDA-approved FCS treatment.","Annual peak net sales guidance for olezarsen in sHTG increased to >$2B from >$1B following strong Phase 3 data.","Submitted sNDA for olezarsen in severe hypertriglyceridemia; potential approval and launch anticipated in 2026.","Expects 2026 launches of zilganersen for Alexander disease (NDA in Q1) and bepirovirsen for chronic hepatitis B (with GSK).","Five Phase 3 readouts from partnered programs planned in 2026, including pelacarsen (Novartis) and eplontersen (AstraZeneca)."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":203330000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115242,"accession_number":"0001140361-26-000435","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Bepirovirsen Phase 3 positive: primary endpoint met, functional cure rates superior to SOC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Over 1,800 patients enrolled in two Phase 3 studies (B-Well 1 & 2) across 29 countries.","Bepirovirsen + SOC achieved statistically significant functional cure rates vs. SOC alone on all ranked endpoints.","Ionis eligible for up to $150M in regulatory/sales milestones plus 10-12% tiered royalties.","Global regulatory submissions planned from Q1 2026; potential first finite 6-month CHB therapy.","Drug has Fast Track FDA, Breakthrough Therapy China, and SENKU Japan designations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131664,"accession_number":"0001193125-25-284609","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Ionis closes $770M 0% convertible notes offering, repurchases $200M of 2026 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $770M aggregate principal of 0.00% Convertible Senior Notes due 2030 (including full greenshoe), net proceeds ~$751.2M.","Used ~$267.6M of net proceeds to repurchase $200M of existing 2026 convertible notes via concurrent transactions.","Remaining proceeds for further repurchases of 2026 notes and general corporate purposes.","Initial conversion rate: 10.1932 shares/$1,000, conversion price ~$98.10 (35% premium over Nov 12 close of $72.67).","Notes mature Dec 1, 2030, no regular interest, redeemable after Dec 6, 2028 if stock ≥130% of conversion price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131663,"accession_number":"0001140361-25-041225","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Ionis reports Phase 3 olezarsen results: 72% TG reduction, 85% fewer pancreatitis events","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: up to 72% placebo-adjusted mean reduction in fasting triglycerides at 6 months, sustained through 12 months (p<0.001).","85% reduction in acute pancreatitis events (p<0.001); 86% of patients achieved TG <500 mg/dL, below risk threshold.","Favorable safety profile; serious AEs lower in olezarsen (9-11%) vs placebo (14%); most common AE mild injection site reactions.","sNDA for 50 mg and 80 mg doses to be submitted to FDA by end of 2025; PDUFA target action date in 2026.","Data presented at AHA Scientific Sessions and simultaneously published in The New England Journal of Medicine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131661,"accession_number":"0001140361-25-040220","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K/A","filed_at":"2025-11-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ionis enters advisory agreement with retiring executive Richard Geary","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Advisory Services Agreement with Richard Geary effective Jan 16, 2026 through Feb 13, 2027.","Total fee of $300,000, plus up to $400/hour for hours over 16/week, capped at $450,000 total.","Geary will provide up to 16 hours/week of advisory services following retirement from Ionis.","Agreement includes standard confidentiality, non-solicitation, and invention assignment clauses.","Either party may terminate with 15 days' written notice; equity acceleration triggered on change in control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131662,"accession_number":"0001140361-25-039650","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ionis Q3 revenue $157M, up 17% YoY; raises FY 2025 guidance on TRYNGOLZA strength","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["TRYNGOLZA Q3 net sales $32M, ~70% QoQ increase; FY guidance raised to $85-95M.","Olezarsen Phase 3 sHTG: 72% TG reduction, 85% AP reduction; sNDA by year-end 2025.","Zilganersen positive pivotal in Alexander disease; NDA submission planned Q1 2026.","Total revenue guidance raised to $875-900M; non-GAAP op loss guided to $275-300M.","Cash and investments $2.2B as of Sep 30; DAWNZERA launched in August 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":740381000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148225,"accession_number":"0001140361-25-035634","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Ionis reports positive pivotal study results for zilganersen in Alexander disease; NDA planned Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: gait speed improved 33.3% vs control (p=0.0412) at week 61 in 50 mg cohort.","No approved disease-modifying treatments for Alexander disease; first investigational drug to show positive impact.","Safety profile favorable: most adverse events mild/moderate; SAEs numerically lower in zilganersen arm.","NDA submission to FDA targeted for Q1 2026; evaluating U.S. Expanded Access Program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148224,"accession_number":"0001140361-25-033541","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Ionis reports positive Phase 3 results for olezarsen in sHTG: 72% triglyceride drop, 85% pancreatitis reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Olezarsen achieved 72% placebo-adjusted mean reduction in fasting triglycerides in Phase 3 CORE study (p<0.0001)","Olezarsen reduced acute pancreatitis events by 85% (p=0.0002) in pooled analysis of CORE and CORE2 studies","Over 90% of patients from CORE/CORE2 enrolled in open-label extension study","Ionis plans to submit sNDA to FDA for olezarsen in sHTG by end of year"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148223,"accession_number":"0001140361-25-032176","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2025-08-21T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA approves Ionis' DAWNZERA (donidalorsen) for HAE prophylaxis in patients 12+","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["First and only RNA-targeted HAE medicine; self-administered every 4 or 8 weeks via autoinjector.","Phase 3 OASIS-HAE: Q4W reduced monthly attack rate 81% vs placebo (primary endpoint); 87% from second dose.","OASISplus OLE: 94% attack rate reduction after one year; switch cohort reduced attacks 62% vs prior therapy.","Ionis' second independent launch in nine months; 84% of patients surveyed preferred DAWNZERA over prior treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148222,"accession_number":"0001140361-25-027949","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ionis Q2 revenue doubles to $452M; raises FY 2025 guidance, TRYNGOLZA sales $19M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $452M (up from $225M); GAAP income from ops $140M vs loss $66M year ago.","TRYNGOLZA net product sales $19M in Q2, first half $26M; SPINRAZA royalties $54M, WAINUA royalties $10M.","FY 2025 guidance raised: total revenue $825-850M (from $725-750M); TRYNGOLZA sales guided at $75-80M.","Donidalorsen expected approval Aug 21, 2025; Phase 3 olezarsen sHTG data due September.","Received $280M upfront from sapablursen license; cash & investments $2.3B; CFO raised non-GAAP op loss guidance to $300-325M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":583660000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166994,"accession_number":"0001140361-25-022267","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Ionis CDO Richard Geary retiring Jan 2026; Holly Kordasiewicz to succeed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard Geary, EVP & chief development officer, will retire effective January 2026 after 30 years at Ionis.","Holly Kordasiewicz, currently SVP neurology, to become EVP & chief development officer in January 2026.","Geary led 50+ IND submissions and 6 FDA/EU approvals including TRYNGOLZA; will stay as strategic consultant in 2026.","Kordasiewicz has 20 years R&D experience and played key role in QALSODY and IONIS-MAPT Rx Alzheimer's program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166993,"accession_number":"0001140361-25-022001","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Ionis annual meeting: all director nominees elected; equity plan increased by 4M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All four director nominees elected: Diaz (134.5M for), Hayden (133.3M), Klein (127.1M), Loscalzo (108.8M).","Say-on-pay resolution approved with 132.6M votes in favor (95.9% of votes cast).","Amendment to 2011 Equity Incentive Plan approved; authorized shares increased by 4M to 42.5M.","Ratification of Ernst & Young as 2025 independent auditors approved with 144.6M votes in favor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166992,"accession_number":"0001140361-25-019620","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ionis announces positive Phase 3 Essence study of olezarsen in moderate hypertriglyceridemia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: placebo-adjusted 61% (80 mg) and 58% (50 mg) reduction in TG at 6 months (p<0.0001).","Met all key secondary endpoints; majority of participants achieved normal TG <150 mg/dL.","Favorable safety profile; most common AE was mild injection site reactions.","Study enrolled 1,478 participants with moderate HTG on standard-of-care lipid-lowering therapy.","Pivotal Phase 3 CORE and CORE2 data in sHTG expected Q3 2025; potential sNDA filing by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166991,"accession_number":"0001140361-25-016562","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ionis Q1 revenue up 10% to $132M; TRYNGOLZA brings $6M, guidance raised >20%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $132M (+10% YoY); TRYNGOLZA product sales $6M; royalty revenue $64M (SPINRAZA $48M, WAINUA $9M).","GAAP operating loss $146M (non-GAAP $117M); FY2025 revenue guidance raised to $725-750M from >$600M.","Donidalorsen PDUFA Aug 21, 2025; olezarsen Phase 3 sHTG data Q3 2025; ION582 Phase 3 Angelman Q2 2025.","Sapablursen licensed to Ono for $280M upfront; potential $660M milestones plus mid-teen royalties.","Cash & investments $2.1B at Mar 31; expected ~$1.9B year-end after $280M Q2 inflow."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":131612000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184374,"accession_number":"0001140361-25-008178","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ionis licenses sapablursen to Ono for $280M upfront, up to $660M milestones and mid-teen royalties","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$280M upfront payment; up to $660M in development, regulatory and sales milestones.","Sapablursen is an investigational RNA-targeted medicine for polycythemia vera; has FDA orphan drug and Fast Track designations.","Ono receives exclusive global rights; Ionis completes Phase 2 IMPRSSION study, Ono handles subsequent development and commercialization.","Ionis eligible for royalties in the mid-teen percentage range on annual net sales of sapablursen.","Transaction subject to Hart-Scott-Rodino Antitrust Improvements Act (HSR) review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184373,"accession_number":"0001140361-25-005080","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ionis Q4 rev $227M, FY rev $705M; 2025 guidance rev >$600M, non-GAAP op loss <$495M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 total revenue $705M exceeded guidance; operating loss $475M GAAP, $345M non-GAAP.","WAINUA launched Jan 2024: $85M product sales, $20M royalties; 84% QoQ growth in Q4.","TRYNGOLZA approved Dec 19, 2024 for FCS; first independent launch underway.","Donidalorsen PDUFA date Aug 21, 2025 for HAE; OLE data shows 96% sustained mean attack rate reduction.","2025 guidance: revenue >$600M, non-GAAP op loss <$495M, cash ~$1.7B."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":226577000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200971,"accession_number":"0001140361-24-050057","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA approves Ionis' Tryngolza (olezarsen) as first treatment for familial chylomicronemia syndrome","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Phase 3 Balance trial: placebo-adjusted mean triglyceride reduction 42.5% at 6 months (p=0.0084), 57% at 12 months.","Acute pancreatitis events: 1 patient (5%) on Tryngolza vs 7 patients (30%) on placebo over 12 months.","Most common adverse reactions: injection site reactions (19% vs 9%), decreased platelets (12% vs 4%), arthralgia (9% vs 0%).","U.S. launch expected before year-end; first of four independent launches planned over next three years.","FCS affects up to ~3,000 people in U.S.; Tryngolza is self-administered monthly via auto-injector."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200970,"accession_number":"0001140361-24-045370","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ionis Q3 revenue $134M (-7% YoY); reaffirms 2024 P&L guidance; increases cash guidance to $2.2B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total revenue $134M vs $144M YoY; commercial revenue $76M, R&D revenue $58M.","WAINUA royalty revenue $5M in Q3 ($10M YTD); SPINRAZA royalties $57M in Q3 ($152M YTD).","Olezarsen PDUFA Dec 19, 2024 for FCS; donidalorsen PDUFA Aug 21, 2025 for HAE.","Cash & investments $2.5B at Sep 30; raised ~$500M from 11.5M-share offering at $43.50.","Phase 3 ION582 for Angelman syndrome to begin H1 2025 after positive FDA end-of-Phase 2 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":478562000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216980,"accession_number":"0001193125-24-217333","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ionis raises ~$500M in public offering of 11.5M shares at $43.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 11.5M shares of common stock at $43.50 per share; gross proceeds ~$500.3M.","Underwriters have 30-day option to purchase up to an additional 1.725M shares.","Offering closed September 11, 2024; lead underwriters Morgan Stanley and Goldman Sachs.","Proceeds not specified; offering conducted under existing shelf registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216979,"accession_number":"0001193125-24-215939","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Ionis proposes public offering of common stock; no size or price disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed preliminary prospectus supplement on Sep 9, 2024 for a registered underwritten public offering of common stock.","No specific number of shares, price range, or use of proceeds disclosed; offering subject to market conditions.","Business update in supplement notes five marketed drugs, nine Phase 3 programs, and key milestones like olezarsen PDUFA Dec 19, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216978,"accession_number":"0001140361-24-035233","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ionis Q2 revenue $225M (+20% YoY); operating loss narrows to $66M; key pipeline milestones","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $225M (up 20% YoY); loss from operations $66M vs $91M loss in Q2 2023; non-GAAP loss from ops $35M.","WAINUA Q2 royalty revenue $4M; approved in Canada; U.S. launch progressing with AstraZeneca.","Olezarsen NDA for FCS accepted for Priority Review, PDUFA Dec 19, 2024; Phase 3 sHTG studies fully enrolled, data H2:2025.","Donidalorsen Phase 3 OASIS data published in NEJM; preparing U.S. NDA and EU MAA for HAE.","Cash and short-term investments $2.1B; reaffirmed 2024 guidance; projects year-end cash $1.7B."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":344748000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236733,"accession_number":"0001140361-24-030447","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ionis expands Otsuka license for donidalorsen in Asia-Pacific; $20M upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Otsuka gains exclusive rights to commercialize donidalorsen (HAE) in Asia-Pacific; Ionis retains US rights.","Ionis receives $20M upfront, plus milestone payments and tiered royalties similar to the Europe deal.","Ionis plans to file U.S. NDA for donidalorsen in 2024 and launch independently if approved.","Otsuka will handle Asia-Pacific and Europe regulatory filings and commercialization; Ionis leads global development.","Positive Phase 3 OASIS-HAE and OASISplus results were recently published in NEJM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236732,"accession_number":"0001140361-24-029588","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Ionis shareholders elect directors and approve all proposals at 2024 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Brett P. Monia re-elected with 120.5M votes for, 2.9M against; Michael Yang re-elected with 109.1M for, 14.2M against.","Advisory say-on-pay approved with 118.9M for, 4.2M against (96.6% support).","Amendment to 2011 Equity Incentive Plan to increase shares by 3.3M to 38.5M approved (96.5M for, 26.9M against).","Ratification of Ernst & Young as independent auditors approved with 129.9M for, 3.5M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236731,"accession_number":"0001140361-24-028247","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ionis reports positive Phase 3 results for donidalorsen in HAE; 81% attack reduction vs placebo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Donidalorsen met primary endpoint: 81% lower monthly HAE attack rate with Q4W dosing vs placebo (p<0.001) over 24 weeks.","OASISplus OLE showed continued improvement: 93% (Q4W) and 92% (Q8W) attack rate reduction from baseline after one year.","Switch cohort: patients switching from prior prophylactic to donidalorsen had 62% further reduction in mean monthly attack rates; 84% preferred donidalorsen.","Donidalorsen was well-tolerated; no related serious TEAEs. Injection site reactions most common AE.","Ionis plans to file NDA with FDA this year; Otsuka preparing MAA in Europe for donidalorsen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236730,"accession_number":"0001140361-24-024648","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ionis Q1 revenue $119M, loss $150M; WAINUA launch delivers $1M royalty; olezarsen NDA filed for FCS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 total revenue $119M, down 9% YoY from $131M; GAAP operating loss $150M vs $114M prior year.","SPINRAZA royalties $38M (down from $50M); WAINUA contributed $1M royalty in first partial quarter of launch.","Cash and short-term investments $2.2B; 2024 financial guidance reaffirmed.","Olezarsen NDA submitted to FDA for FCS; positive Phase 3 donidalorsen data for HAE, preparing regulatory submissions.","Pipeline progress: eplontersen fast track for ATTR cardiomyopathy, bepirovirsen fast track for CHB, ION224 positive Phase 2 for MASH."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":119497000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236729,"accession_number":"0001140361-24-018449","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2024-04-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ionis Phase 3 Balance study of olezarsen meets primary endpoint; reduces acute pancreatitis in FCS","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Olezarsen 80 mg reduced fasting triglycerides by 44% vs placebo at 6 months (p<0.001).","Acute pancreatitis events: 1 event in 80 mg group vs 11 in placebo over 12 months.","All-cause hospitalizations reduced by 84% (placebo-adjusted) from baseline to 12 months.","No serious treatment-emergent AEs related to olezarsen; serious AEs 14% (80 mg) vs 39% placebo.","Ionis to pursue regulatory approval for first potential FCS treatment in U.S.; data published in NEJM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254358,"accession_number":"0001140361-24-010288","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["5.02","1.01","9.01"],"status":"ready","headline":"Ionis announces Kyle Jenné returns as EVP Commercial; Onaiza Cadoret-Manier departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kyle Jenné rejoins as executive vice president, commercial, effective Feb 29, 2024.","Onaiza Cadoret-Manier, EVP chief global product strategy and operations officer, leaves for another opportunity.","Cadoret-Manier will remain full-time through March 15, 2024, then serve as advisor.","Advisory agreement pays $12,500/month through Sep 2024, then $6,250/month through Jan 10, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254357,"accession_number":"0001140361-24-008700","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ionis Q4 revenue $325M, up 114%; WAINUA approved; 2024 guidance: revenue >$575M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $325M (up 114% YoY); full year revenue $788M (up 34%); Q4 operating loss narrowed to $6M from $208M.","WAINUA (eplontersen) FDA-approved for ATTRv-PN; U.S. launch underway; $50M milestone from AstraZeneca.","Positive Phase 3 data for olezarsen (FCS) and donidalorsen (HAE); preparing regulatory submissions.","2024 guidance: revenue >$575M, non-GAAP operating loss <$475M, cash ~$1.7B.","SPINRAZA royalties $240M in 2023; QALSODY royalties included; pipeline milestones with bepirovirsen, ION582."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":324505000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254356,"accession_number":"0001140361-24-002995","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2024-01-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ionis announces positive Phase 3 results for donidalorsen in HAE; NDA submission planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Donidalorsen met primary endpoint: significant reduction in HAE attack rate for Q4W (p<0.001) and Q8W (p=0.004) vs placebo.","Favorable safety profile; no serious adverse events in donidalorsen-treated patients.","Ionis preparing NDA submission to U.S. FDA; Otsuka preparing MAA to European Medicines Agency.","Third positive Phase 3 readout in 12 months, underscoring LICA platform strength.","Over 90% of OASIS-HAE patients completed and entered OASIS-Plus open-label extension study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271834,"accession_number":"0001140361-23-058974","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2023-12-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA approves Ionis/AstraZeneca WAINUA (eplontersen) for hATTR polyneuropathy","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Approval based on Phase 3 NEURO-TTRansform 35-week interim; co-primary endpoints of serum TTR and mNIS+7 and Norfolk QoL-DN showed sustained benefit.","WAINUA is the only self-administered auto-injector treatment for ATTRv-PN; available in U.S. in January 2024.","Global regulatory reviews underway; AstraZeneca holds commercialization rights outside U.S., recently expanded to Latin America.","Eplontersen also in Phase 3 CARDIO-TTRansform for ATTR-CM, fully enrolled with >1,400 patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271833,"accession_number":"0001140361-23-058152","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2023-12-18T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ionis licenses donidalorsen European rights to Otsuka; $65M upfront, tiered royalties","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Otsuka receives exclusive European commercialization rights to donidalorsen (HAE prophylactic).","Ionis gets $65M upfront plus undisclosed regulatory/sales milestones.","Ionis eligible for tiered royalties of 20-30% on European net sales.","Ionis retains U.S. commercialization rights; plans to launch independently if approved.","Phase 3 donidalorsen data expected H1 2024; Phase 2 OLE showed 96% attack rate reduction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271832,"accession_number":"0001140361-23-057644","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Ionis appoints Michael Yang to Board of Directors, expanding board to 10","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Yang appointed to Ionis board effective December 14, 2023.","Yang most recently served as CEO of ViaCyte, acquired by Vertex in 2022.","Former EVP & Chief Commercial Officer at Acadia Pharmaceuticals (2017-2021).","Yang previously President of Janssen Biotech, generating over $8B in annual revenues.","Will receive standard non-employee director cash and equity compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271831,"accession_number":"0001140361-23-051047","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ionis Q3 2023 revenue $144M, net loss $143M; eplontersen on track for Dec 2023 U.S. approval","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $144M (-10% YoY); SPINRAZA royalties $67M flat; R&D revenue $60M down from $87M.","Operating expenses $287M (+31% YoY); loss from operations $143M vs. $59M loss in Q3 2022.","Cash and short-term investments $2.2B; reaffirmed 2023 financial guidance.","Eplontersen regulatory submissions accepted in EU and Canada; potential U.S. approval in Dec 2023.","Olezarsen Phase 3 Balance study met endpoints: significant triglyceride lowering, reduced pancreatitis attacks; on track for early 2024 filings."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":463142000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288686,"accession_number":"0001140361-23-045401","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2023-09-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ionis signs $60M upfront deal with Roche for two RNA programs for Alzheimer's and Huntington's","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ionis receives $60M upfront; Roche gains exclusive worldwide rights to develop and commercialize two undisclosed RNA-targeting medicines.","Ionis responsible for pre-clinical advancement; Roche leads clinical development, manufacturing, and commercialization.","Ionis eligible for development, regulatory, and commercial milestone payments plus tiered royalties.","Programs target Alzheimer's disease and Huntington's disease; expands 10-year partnership including tominersen for HD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288685,"accession_number":"0001140361-23-045170","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2023-09-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ionis reports positive Phase 3 olezarsen results; 100% reduction in pancreatitis in FCS","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Olezarsen 80 mg achieved primary endpoint with significant triglyceride reduction vs placebo (p=0.0009) at six months.","Acute pancreatitis events reduced 100% (0 events for olezarsen vs 11 for placebo) over 12 months.","Favorable safety profile; no hepatic/renal toxicity, no clinically meaningful platelet reductions.","Ionis plans to file NDA with FDA early 2024; potential first approved treatment for FCS in US.","Phase 3 studies continuing in broader severe hypertriglyceridemia (SHTG) population."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288684,"accession_number":"0001140361-23-041038","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2023-08-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Ionis repurchases $30.2M of 0.125% convertible notes due 2024 for $29.2M cash","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Agreements with certain holders on Aug 21 and Aug 23, 2023; $30.2M principal bought for ~$29.2M cash.","Repurchases were privately negotiated; no impact on note terms for remaining holders.","Company may seek to buy back additional 2024 notes or other debt in open market or private deals.","Retirement of notes reduces outstanding principal and interest obligations.","Future repurchases could be material and affect trading liquidity of the notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288683,"accession_number":"0001140361-23-040746","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2023-08-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Ionis closes sale of Carlsbad lots and enters leaseback with Oxford affiliate","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Sold Lots 21 and 22 in Carlsbad Oaks North Business Park to Oxford I Asset Management USA Inc.","Closed lease agreement on same property with affiliate Lots 21 & 22 Owner (DE) LLC.","Purchase and sale agreement originally entered October 20, 2022; lease terms summarized in prior 8-K.","Transaction closed on August 21, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288682,"accession_number":"0001140361-23-038715","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ionis Q2 2023 revenue up 40% to $188M; eplontersen PDUFA set for Dec 22, 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $188M in Q2 (+40% YoY); operating loss $91M GAAP, $64M non-GAAP.","Cash & short-term investments $2.4B; issued $575M notes due 2028 at 1.75%, repurchased $434M of 2024 notes.","Eplontersen Phase 3 shows improvement through 85 weeks; PDUFA date Dec 22, 2023.","Donidalorsen OASIS-HAE and eplontersen CARDIO-TTRansform enrollment complete; data H1:2024 and H1:2025.","SPINRAZA royalties flat at $61M in Q2; Biogen's QALSODY approved for SOD1-ALS."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":318935000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288681,"accession_number":"0001140361-23-038087","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2023-08-04T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"IONIS terminates lease for 217K sq ft Oceanside facility after landlord misses July 31 grading milestone","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Notified Sudberry Development of termination under Section 2.3 of Lease due to failure to commence grading by July 31, 2023.","Lease for ~217,000 rentable sq ft manufacturing/R&D/office/warehouse on 13.1 acres in Oceanside, CA; base rent at fair market value based on construction cost.","Termination effective Aug 31, 2023 unless landlord achieves milestone by then; no further rights or obligations after.","Company states termination will not impact ability to successfully commercialize its medicines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288680,"accession_number":"0001140361-23-037887","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ionis and Novartis expand Lp(a) collaboration; Ionis gets $60M upfront for next-gen therapy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ionis receives $60 million upfront from Novartis for next-generation Lp(a) compound.","Builds on existing pelacarsen collaboration; Novartis to handle development and commercialization.","Agreement subject to HSR antitrust clearance.","Ionis eligible for additional milestone payments and tiered royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12640933009.072567,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-08-03T23:59:59+00:00|288680"}